S
Scott A. Biller
Researcher at Agios Pharmaceuticals
Publications - 33
Citations - 4044
Scott A. Biller is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Cellular differentiation & Mutant. The author has an hindex of 18, co-authored 33 publications receiving 3197 citations.
Papers
More filters
Journal ArticleDOI
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle,Janeta Popovici-Muller,Nicolaos Palaskas,Sevin Turcan,Christian Grommes,Carl Campos,Jennifer Tsoi,Owen Clark,Barbara Oldrini,Evangelia Komisopoulou,Kaiko Kunii,Alicia Pedraza,Stefanie Schalm,Lee Silverman,Alexandra Miller,Fang Wang,Hua Yang,Yue Chen,Andrew Kernytsky,Marc K. Rosenblum,Wei Liu,Scott A. Biller,Shinsan M. Su,Cameron Brennan,Timothy A. Chan,Thomas G. Graeber,Katharine E. Yen,Ingo K. Mellinghoff,Ingo K. Mellinghoff +28 more
TL;DR: The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy, and isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers, is examined.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis
Monika Bambouskova,Laurent Gorvel,Vicky Lampropoulou,Alexey Sergushichev,Ekaterina Loginicheva,Kendall Johnson,Daniel Korenfeld,Mary Elizabeth Mathyer,Hyeryun Kim,Li-Hao Huang,Dustin Duncan,Howard Bregman,Abdurrahman Keskin,Andrea Santeford,Rajendra S. Apte,Raghav Sehgal,Britney Johnson,Gaya K. Amarasinghe,Miguel P. Soares,Takashi Satoh,Shizuo Akira,Tsonwin Hai,Cristina de Guzman Strong,Karine Auclair,Thomas P. Roddy,Scott A. Biller,Marko Jovanovic,Eynav Klechevsky,Kelly M. Stewart,Gwendalyn J. Randolph,Maxim N. Artyomov +30 more
TL;DR: The immunoregulatory metabolite itaconate and its dimethyl derivative induce electrophilic stress and react with glutathione to induce both Nrf2-dependent and NRF2-independent responses, resulting in AF3-mediated inhibition of the inflammation-related protein IκBζ.
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.